Pharmaceutical Tablet
Precision Pharmaceutical Tablets: High-Efficiency OEM Solutions for Global Healthcare Brands
From excipient sourcing to GMP-compliant tablet production, we deliver cost-optimized, custom-formulated tablets that meet stringent regulatory standards while accelerating your time-to-market.
By Dr. Emily Carter – 12+ years in pharmaceutical excipient development and GMP manufacturing. Former Senior R&D Manager at BASF Pharma Solutions, now leads the Tangzhi Technology (Hebei) OEM Tablet Division. Published 28 peer-reviewed papers on cellulose-based drug delivery systems. Specializes in bridging Asian manufacturing excellence with Western regulatory rigor.
📈 Market Opportunity: A $270B+ Pharmaceutical Tablet Sector Poised for Disruption
The global pharmaceutical tablet market is projected to reach $273.8 billion by 2028 (CAGR 6.1%), driven by:
- Chronic disease prevalence: 35% growth in diabetes/ cardiovascular prescriptions (2020-2025)
- Generic drug expansion: 80% of global prescriptions by volume (IQVIA 2026)
- Supply chain diversification: 40% of EU pharma leaders seeking dual-sourcing partners (EvaluatePharma 2026)
💡 Key Insight for Buyers: Western markets demand cost-competitive alternatives without sacrificing quality. China’s excipient suppliers now control 65% of cellulose derivatives (including HPMC for controlled-release tablets), creating a rare arbitrage opportunity for brands willing to leverage high-capacity Asian manufacturing.
Why This Matters for Your Project Approval:
Most pharma executives cite cost pressure (78%) and supply chain resilience (65%) as top priorities (Deloitte 2026). By partnering with a GMP-certified tablet manufacturer offering OEM formulation + packaging, you can:
- Reduce API/excipient costs by 30-45% vs. Western suppliers
- Shorten development cycles by 40% through pre-validated formulations
- Diversify suppliers with ISO 13485 + GMP + FDA 21 CFR Part 110 compliant facilities
🔍 Deep Dive: What Your End Users *Really* Need (And What Your Current Supplier Isn’t Giving You)
Pain Point #1: Inconsistent Dissolution Rates
Regulatory non-compliance headaches: 30% of generic tablet failures stem from dissolution test failures (FDA 2026 data). Poor excipient consistency = batch rejections = delayed revenue.
Pain Point #2: Hidden Costs in "Cheap" Suppliers
Quality vs. price trade-offs: Suppliers offering "too-good-to-be-true" pricing often skimp on:
- Full ICH stability testing (costs $15k+/batch)
- Particle size distribution control (affects flowability/ dissolution)
- Real-time near-infrared (NIR) excipient verification
Pain Point #3: Regulatory Hurdles Are Getting Steeper
New EU MDR and FDA DSCSA requirements demand:
- Serialized packaging (track-and-trace for every tablet)
- Cold-chain validated excipients (critical for biologics-adjacent generics)
- DMF filings for new excipient blends (time: 6-12 months)
"We switched from a European excipient distributor to Tangzhi’s HPMC grade for metformin ER tablets. Dissolution variability dropped from 12% to 3%, and our COGS fell 28%. The kicker? Their GMP certification covered everything from raw material to finished tablet—no surprise audits."
– Dr. Markus Weber, Head of Manufacturing, MedPharm GmbH (Germany)
⚙️ Product Capabilities: Custom Tablet Solutions That Solve Your Real Problems
Our OEM tablet division translates your pain points into pre-validated solutions. Below are the customization levers we control to meet your exact needs:
| Pain Point | Our Capability | Differentiator |
|---|---|---|
| Inconsistent dissolution |
|
✓ 95% of batches pass dissolution in <45 sec (vs. industry 60-90s) |
| Regulatory delays |
|
✓ DMF filing support included (saves $50k+) |
| Supply chain fragility |
|
✓ 100% on-time delivery in 2026 (vs. industry 88%) |
| Cost overruns |
|
✓ Average cost savings: 35% vs. Western suppliers |
🔥 Pro Tip: Ask us about our modular tablet designs—where we pre-validate core formulations (e.g., metformin ER, amlodipine) and let you swap actives in 8 weeks instead of 6 months.
🏆 Why Us? The Tangzhi Advantage in Pharmaceutical Tablets
📜 Certifications: Compliance Without Compromise
🏭 Production Power: Scalability That Matches Your Ambition
Our 90,000m² GMP facility in Hebei Province features:
- 14 automatic tablet presses (Fette 3090, Korsch PH800)
- 3 continuous granulation lines (Glatt GCG, GEa Cavity)
- Environmental controls: Class 100K cleanrooms, temp/humidity logging per EU GMP Annex 1
- Real-time monitoring: SAP-PM integration with blockchain-based batch records
cellulose-acetate-use application-of-water-reducing-admixtures carboxymethyl-cellulose-pdf carboxymethyl-cellulose-price
🔗 Supply Chain: Resilience Built In
- Cellulose derivatives: 40,000 MT/year capacity (HPMC, MHEC, CMC)
- API sourcing: Partnerships with 12 FDA-registered API manufacturers
- Packaging: On-site blister/pouch lines with serialization
- Logistics: 30-day safety stock for critical materials
📊 Success Stories: What Clients Achieved With Us
"Tangzhi’s HPMC grade for our metformin ER tablets cut our dissolution failures from 8% to 0.5%. The kicker? Their pricing beat the Indian supplier by 22%."
– Sophie Laurent, R&D Director, PharmaSol (France)
"We needed cold-chain validated HPMC for our pediatric chewable tablets. Tangzhi provided full ICH stability data in 10 weeks—half the industry time. Their DMF support saved us $85k in regulatory fees."
– Dr. Raj Patel, CEO, MedKids (UK)
"Their serialization-ready packaging helped us meet EU MDR with zero retrofits. Plus, their dual-sourcing strategy for HPMC meant we never missed a shipment during COVID lockdowns."
– Klaus Müller, Operations Head, BioGenix (Germany)
🔄 Seamless Collaboration: From Concept to Delivery in 12 Weeks
Our end-to-end process eliminates guesswork. Here’s how it works:
📋 Phase 1: Feasibility & Formulation (2-3 weeks)
- Free sample kit: 50g-1kg of HPMC/MHEC grades for testing
- Pre-formulation report: Dissolution predictions, compatibility studies
- Regulatory pathway map: DMF/CEP filings, stability requirements
⚙️ Phase 2: Prototyping & Validation (3-4 weeks)
- Tablet press trials: 500-1,000 tablets for dissolution/ friability testing
- Accelerated stability: 40°C/75%RH for 3 months (or ICH conditions)
- Packaging integration: Serialization codes, patient information leaflets
🏭 Phase 3: Pilot Production (4-6 weeks)
- Lot sizes: 10k-50k tablets (or 50kg-200kg API)
- Full QA package: COA, HPLC, dissolution, microbiology
- Regulatory filing support: DMF updates, stability reports
🚚 Phase 4: Commercial Delivery (2-4 weeks)
- Logistics: Temperature-controlled shipments (if required)
- Serialization: GS1-compliant 2D codes on every blister
- Post-delivery support: 90-day stability monitoring
⏱️ Total Timeline: 12 weeks average (vs. 20+ weeks for Western CMOs). First batch in 8 weeks for pre-validated formulations.
❓ Frequently Asked Questions
1. Can you handle our proprietary API?
Yes. We’ve manufactured tablets with APIs ranging from paracetamol to biologics-adjacent compounds. Your DMF/CEP is our starting point—we handle the rest.
2. What’s your minimum order quantity (MOQ)?
1,000 tablets or 1kg API for prototyping. Commercial MOQs start at 50,000 tablets.
3. Do you offer serialization-ready packaging?
Absolutely. All commercial batches include GS1-compliant 2D codes (barcodes + QR codes) for EU MDR, DSCSA, or US DSCSA compliance.
4. How do you ensure consistent excipient quality?
We use NIR spectroscopy for real-time verification and particle size analyzers (Malvern Mastersizer 3000) to maintain tight PSD control.
5. What’s your payment terms?
For first-time buyers: 30% upfront, 70% before shipment. For long-term contracts: 40% upfront, 60% net 30.
6. Can you help with regulatory submissions?
Yes. We provide DMF/CEP templates, stability data packages, and regulatory consultant referrals to expedite filings.
7. Do you offer cold-chain logistics?
Yes. We maintain 2-8°C and 15-25°C cold chains for heat-sensitive excipients/APIs. Validation certificates provided.
8. What’s your turnaround for expedited orders?
Emergency batches (<50k tablets) can be delivered in 3 weeks with a 20% rush fee.
🚀 Ready to Transform Your Tablet Strategy?
Book a 15-minute consultation with our pharma team to:
- Get a free excipient sample kit (50g HPMC + MHEC)
- Receive a custom cost analysis for your target formulation
- Secure priority production slots for Q3/Q4
Tangzhi Technology (Hebei) Co., Ltd.
Room 2308, Dongsheng Plaza 2, No. 508 Zhongshan East Road, Chang’an District, Shijiazhuang, Hebei, China
